| |
Nottingham, United Kingdom, 06/05/2009 – Novozymes Biopharma, part of Novozymes, world leader in bioinnovation, will be showcasing its animal-free cell culture portfolio on booth #40 at the 21st Meeting of the European Society for Animal Cell Technology (ESACT) 7-10 June 2009, CityWest Hotel, Dublin, Ireland.
As part of its cell culture portfolio, Novozymes Biopharma will be showcasing its' products within the CellPrime brand. This includes two newly launched products, CellPrime rTransferrin AF, and CellPrime rAlbumin AF-G. Both products are manufactured by Novozymes Biopharma and sold exclusively through Millipore Corporation as part of the CellPrime alliance.
CellPrime rTransferrin AF is the first animal-free alternative to serum-derived human or bovine transferrin for industrial cell culture and upstream biopharmaceutical applications. It is designed to reduce risk and ease regulatory concerns as it improves the consistency of batch quality and productivity of customers' industrial cell culture processes. Manufactured in FDA-inspected facilities to cGMP standards, CellPrime rTransferrin AF is suitable for both research and commercial scale mammalian cell culture.
CellPrime rAlbumin AF-G is an animal free, recombinant human albumin developed specifically for large scale industrial cell culture. It offers multiple benefits including the maintenance of osmotic balance and transport, the distribution of fatty acids and amino acids, as well as improving consistency of customers' industrial cell culture processes.
Novozymes Biopharma will also exhibit LONGR3 IGF-I, an analogue of human insulin-like growth factor I (IGF-I) specifically engineered by Novozymes Biopharma for use in industrial cell culture. LONGR3 IGF-I provides improved performance and a consistent, compliant and animal-free alternative to recombinant insulin. This product is manufactured by Novozymes Biopharma and sold exclusively through SAFC Biosciences.
Novozymes Biopharma will present a number of technical discussions including:
• A presentation entitled "Regulation of IGF-I and transferrin receptor numbers at the cell surface may drive growth and productivity of hybridoma cells" authored by Andrew J Sakko1, Kenneth C Bertram, Sally Grosvenor, Danny Voorhamme, Anthony Simula and Geoffrey L Francis, Novozymes Biopharma AU Ltd. This will be held on Tuesday June 9th at 12pm in the main plenary room, Convention 1 and 2.
• A poster entitled "Recombinant Albumin as an animal-free supplement for cell culture applications" authored by Collette Sheahan, Novozymes Biopharma AU Ltd. This will be held on Tuesday 9th June at 14.40hrs - 17.40hrs held at the Refreshments and Poster Session 1 (Poster # P240)
• A poster entitled "Utilising scale-up model systems to optimise upstream process development" authored by Sally Grosvenor, Larissa Chirkova and Kenneth Bertram, Novozymes Biopharma AU Ltd. This will be held on Wednesday 10th June at 10.30hrs - 13.00hrs held at the Refreshments and Poster Session 2 (Poster # P97)
About Novozymes
Novozymes (novozymes.com) is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.
Novozymes' natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow.
Our never-ending exploration of nature's potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.
Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.
Novozymes Biopharma:
Sally Vernon, Marketing Communications Manager SYKE[.]novozymes.com
Press and media:
Johan Melchior - T: (direct): +45 4446 0690 / T: (mobile): +45 3077 0690
René Tronborg - T: (direct): +45 4446 2274 / T: (mobile): +45 3077 2274
Paige Donnelly (USA) - T: (direct): +1 919 494 3209 / T: (mobile): +1 919 218 4501
Investor relations:
Camilla Kinch Jensen - T: (direct): +45 4446 0852 / T: (mobile): +45 3077 0852
Tobias Bjørklund (USA) - T: (direct): +1 919 494 3483 / T: (mobile): +1 919 649 2565
|
SYKE[.]novozymes.com 
